In the second financial quarter of FY2022, MedMira continued its strategic plan to focus its own product portfolio on the two fastest...

Halifax, Nova Scotia, 4 February, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting (AGM) update on...

By analyzing the mutation sites of N protein and their proportion according to the coronavirus sequences released by the GISAID database,...

Halifax, Nova Scotia, 21 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its VYRATMproduct line by...

We are delighted to announce the receipt of the MDSAP certificate today. This highlights our firm and long lasting commitment to the...